US92764N1028
© BusinessWire
12.01.2026
VIR
LISTED
NASDAQ
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving the combination therapy of tobevibart, an investigational neutralizing monoclonal antibody (mAb), and elebsiran, an investigational small interfering...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
VIR
LISTED
NASDAQ
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California.
A live webcast of the presentation will be made available under Events & Presentat...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for the commercial rights to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Austr...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
19.11.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida.
A live webcast of the presentation will be made available unde...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
10.11.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not det...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.
A live webcast of the presentation will be made available under...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025.
"Our third quarter demonstrated exceptional execution across our clinical portfolio," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "We completed ECLIPSE 1 enrollment approx...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE 1 is one of three trials in Vir Biotechnology’s ECLIPSE registrational program for CHD, and it is...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025.
The corporate update and financial results will be pr...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs). VIR-5500 is an investigational PRO-XTEN® dual-masked T-cell engager (TCE) targeting prostate-specific membrane antigen (P...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone, or in combination with elebsiran, in patients with chronic hepatitis delta in an oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD)...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York.
A live webcast of the fireside chat will be mad...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
31.07.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and elebsiran to continued bulevirtide monotherapy in participants with chronic hepatitis delta (CHD) who have not achieved undetectable hepatitis delta vi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager (TCE) targeting EGFR (epidermal growth factor receptor). VIR-5525 will be evaluated for the treatment of a variety of EGFR-expressing solid tumors in...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2025, on August 6, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on August 6, 2025.
The corporate update and financial results will be provided v...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida.
A live webcast of the fireside chat will be m...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada.
A live webcast of the fireside chat will be made avai...
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants wit...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.
“The first quarter of 2025 marked significant progress in our mission of powering the immune system to transform lives," said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotec...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025.
The corporate update and financial results will be provided via a pre...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week po...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of th...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024.
“2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising pro...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts.
A live webcast of the fireside chat will be made available under Events & Pres...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
VIR
LISTED
NASDAQ
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025.
The corporate update and financial re...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles wit...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
VIR
LISTED
NASDAQ
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California.
A live webcast of the presentation will be made available under Events & Presentation...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positi...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
VIR
LISTED
NASDAQ
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
News Preview
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN™ platf...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
News Preview
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida.
A live webcast of the fireside chat will be made ava...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
News Preview
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta (CHD). The most-advanced and potential first-of-its-kind investigational human monoclonal antibody and siRNA combination dosed monthly a...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. The study demonstrated promising rates of hepatitis B surface antigen (HBsAg...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
“This quarter was transformational for Vir. We have bolstered our clinical pipeline with three potential best-in-class dual-masked T-cell engagers in oncology, and have sharpened our focus within i...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
VIR
LISTED
NASDAQ
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024.
The corporate update and financial resul...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
News Preview
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of tobevibart, an investigational monoclonal antibody (mAb), and elebsiran, an investigational small interfering ribonucleic acid (siRNA) for the potential treatment of chronic hepatitis...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2024
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
News Preview
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.
A live webcast of the fireside chat wil...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
News Preview
Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne will join the Vir Executive Management Team and report directly to the company’s Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA.
Mr. O’Byrn...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
VIR
LISTED
NASDAQ
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage ma...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2024
VIR
LISTED
NASDAQ
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City.
A live webcast of the fireside chat will...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
